Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filgrastim
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It is used to reduce the incidence and duration of neutropenia and febrile neutropenia in patients undergoing cytotoxic chemotherapy or bone marrow transplantation. It also treats neutropenia caused by other conditions such as HIV/AIDS or radiation exposure. Filgrastim stimulates the production of neutrophils by binding to the G-CSF receptor on hematopoietic cells in the bone marrow and promoting their proliferation and differentiation. The drug is not a cancer treatment but serves as supportive care to lessen bone marrow suppression secondary to cytotoxic treatments.
- Brand names
- NeupogenGranixNivestymReleukoZarxioNypoziAccofilGrastofilRatiograstim
- Other names
- BiocilinBiofigranBiofilgranEndufilFilatilFilgenGranulokineGrimatinInmunefJiexinLeucogenLeucostimMacroleucoNeukine
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filgrastim.